22.05.2020 16:21:35
|
Stock Alert: Synadax Down 18%
(RTTNews) - Shares of Syndax Pharmaceuticals, Inc. (SNDX) are sinking more than 18% Friday morning after the company announced that the phase III E2112 study of its investigational compound entinostat in combination with exemestane in patients with HR+, HER2- advanced breast cancer did not achieve the primary endpoint.
The study was conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI).
Syndax stock is currently trading at $16.71. It has traded in the range of $5.35- $21.97 in the last 52-weeks.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Syndax Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Syndax Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Syndax Pharmaceuticals Inc | 14,00 | -0,71% |
|